Skip to main content
Back
NTLA logo

Intellia Therapeutics, Inc.

Data quality: 67%
NTLA
NASDAQ Healthcare Biotechnology
$13.11
▲ $0.27 (2.10%)
Mkt Cap: 1.55B
Day Range
$12.66 $13.34
52-Week Range
$5.90 $28.25
Volume
3,106,167
50D / 200D Avg
$12.99 / $12.58
Prev Close
$12.84

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -3.8 0.4
P/B 2.9
ROE % 3.8
Net Margin % -609.9 3.9
Rev Growth 5Y % 19.6 10.0
D/E 0.2

Key Takeaways

Revenue grew 19.62% annually over 5 years — strong growth
Negative free cash flow of -354.66M
PEG of 0.09 suggests growth is underpriced
Capital efficient — spends only 8.54% of revenue on capex

Growth

Revenue Growth (5Y)
19.62%
Revenue (1Y)16.92%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROICN/A
Net Margin-609.85%
Op. Margin-651.67%

Safety

Debt / Equity
N/A
Current RatioN/A
Interest Coverage0.00

Valuation

P/E Ratio
-3.75
P/B RatioN/A
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 16.92% Revenue Growth (3Y) 36.58%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 19.62% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 67.67M Net Income (TTM) -412.69M
ROE N/A ROA N/A
Gross Margin 76.47% Operating Margin -651.67%
Net Margin -609.85% Free Cash Flow (TTM) -354.66M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -3.75 P/B Ratio N/A
P/S Ratio 22.89 PEG Ratio 0.09
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.55B Enterprise Value N/A

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 67.67M 57.88M 36.28M 52.12M 33.05M
Net Income -412.69M -519.02M -481.19M -474.19M -267.89M
EPS (Diluted) -3.81 -5.25 -5.42 -6.16 -3.78
Gross Profit 51.75M 47.59M 27.30M 44.55M 26.16M
Operating Income -440.99M -534.26M -515.29M -458.16M -267.85M